ÂÜÀòÂÒÂ×

Taryn joined the Numab team in January 2021 to build and lead the Clinical Operations and Regulatory Affairs functions for the organization. Prior to joining Numab, Taryn served in key leadership positions at Sucampo Pharmaceuticals (now Mallinckrodt) and Mahana Therapeutics, where she played a pivotal role in obtaining global marketing authorizations for Amitiza® capsules and, later, for Parallel™, the first FDA-approved prescription-only digital therapeutic (PDT) intended for use in adults with Irritable Bowel Syndrome (IBS). Taryn brings to Numab expertise in strategic planning for pipeline development programs, spanning the full lifecycle of product development across numerous therapeutic areas, from early phase through post-marketing. She earned her Bachelors of Science degree in Biochemistry and Molecular Biology from Gettysburg College and later obtained her Master of Public Health degree from Johns Hopkins University.